Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anglaret

Showing results (171-180 of 267) with videos related to

Pageof 27
Sort By:
Plos Medicine|October 28, 2009
Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisalElena Losina, Hapsatou Touré, Lauren M Uhler, et al.
Plos One|June 6, 2017
High correlation between Framingham equations with BMI and with lipids to estimate cardiovascular risks score at baseline in HIV-infected adults in the Temprano trial, ANRS 12136 in Côte d'IvoireCalixte Ghehi, Delphine Gabillard, Raoul Moh, et al.
Antiviral Therapy|September 13, 2005
Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Côte d'IvoireRaoul Moh, Christine Danel, Souleymane Sorho, et al.
Annals of Internal Medicine|July 22, 2009
When to start antiretroviral therapy in resource-limited settingsRochelle P Walensky, Lindsey L Wolf, Robin Wood, et al.
The New England Journal of Medicine|September 15, 2006
Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'IvoireSue J Goldie, Yazdan Yazdanpanah, Elena Losina, et al.
Diagnostic Microbiology and Infectious Disease|August 19, 2015
Identifying patients infected with hepatitis B virus in sub-Saharan Africa: potential for misclassificationAnders Boyd, Sarah Maylin, Raoul Moh, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 26, 2013
Increasing rate of TAMs and etravirine resistance in HIV-1-infected adults between 12 and 24 months of treatment: the VOLTART cohort study in Côte d'Ivoire, West AfricaEugène Messou, Marie-Laure Chaix, Delphine Gabillard, et al.
Antiviral Therapy|July 20, 2012
Could early antiretroviral therapy entail more risks than benefits in sub-Saharan African HIV-infected adults? A model-based analysisXavier Anglaret, Callie A Scott, Rochelle P Walensky, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|April 1, 1997
CD4+ T-lymphocyte counts in HIV infection: are European standards applicable to African patients?X Anglaret, S Diagbouga, E Mortier, et al.
AIDS (London, England)|March 23, 2016
Early antiretroviral therapy initiation in west Africa has no adverse social consequences: a 24-month prospective studyKévin Jean, Serge Niangoran, Christine Danel, et al.
Pageof 27

Showing results (171-180 of 267) with videos related to

Sort By:
Pageof 27
Plos Medicine|October 28, 2009
Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisalElena Losina, Hapsatou Touré, Lauren M Uhler, et al.
Plos One|June 6, 2017
High correlation between Framingham equations with BMI and with lipids to estimate cardiovascular risks score at baseline in HIV-infected adults in the Temprano trial, ANRS 12136 in Côte d'IvoireCalixte Ghehi, Delphine Gabillard, Raoul Moh, et al.
Antiviral Therapy|September 13, 2005
Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Côte d'IvoireRaoul Moh, Christine Danel, Souleymane Sorho, et al.
Annals of Internal Medicine|July 22, 2009
When to start antiretroviral therapy in resource-limited settingsRochelle P Walensky, Lindsey L Wolf, Robin Wood, et al.
The New England Journal of Medicine|September 15, 2006
Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'IvoireSue J Goldie, Yazdan Yazdanpanah, Elena Losina, et al.
Diagnostic Microbiology and Infectious Disease|August 19, 2015
Identifying patients infected with hepatitis B virus in sub-Saharan Africa: potential for misclassificationAnders Boyd, Sarah Maylin, Raoul Moh, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 26, 2013
Increasing rate of TAMs and etravirine resistance in HIV-1-infected adults between 12 and 24 months of treatment: the VOLTART cohort study in Côte d'Ivoire, West AfricaEugène Messou, Marie-Laure Chaix, Delphine Gabillard, et al.
Antiviral Therapy|July 20, 2012
Could early antiretroviral therapy entail more risks than benefits in sub-Saharan African HIV-infected adults? A model-based analysisXavier Anglaret, Callie A Scott, Rochelle P Walensky, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|April 1, 1997
CD4+ T-lymphocyte counts in HIV infection: are European standards applicable to African patients?X Anglaret, S Diagbouga, E Mortier, et al.
AIDS (London, England)|March 23, 2016
Early antiretroviral therapy initiation in west Africa has no adverse social consequences: a 24-month prospective studyKévin Jean, Serge Niangoran, Christine Danel, et al.
Pageof 27